Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome

Microcirculation

Volumn 16, Issue 8, 2009, Pages 667-684

  Goodwill, Adam G ^a,b   Frisbee, Stephanie J ^a,c   Stapleton, Phoebe A ^a,c   James, Milinda E ^a,b   Frisbee, Jefferson C ^a,b  

^a Center for Cardiovascular and Respiratory Sciences   (United States)

^b School of Medicine ^*  (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic inflammation; Nitric oxide bioavailability; Regulation of skeletal muscle perfusion; Rodent models of obesity; Vascular reactivity; Vascular remodeling

Indexed keywords

ATORVASTATIN; GEMFIBROZIL; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROBUCOL; RANTES; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; COMORBIDITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HYPERCHOLESTEROLEMIA; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOLES; CYTOKINES; GEMFIBROZIL; HEPTANOIC ACIDS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MICROCIRCULATION; MUSCLE, SKELETAL; NITRIC OXIDE; PROBUCOL; PYRROLES; RATS; RATS, ZUCKER; SIMVASTATIN; TIME FACTORS;

RATTUS; RODENTIA;

EID: 70350678737     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.3109/10739680903133722     Document Type: Article

References (52)

1. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E. (2005). Nitric oxide modulates vascular infl ammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol 289:H228-H236.
2. Baumbach GL, Hajdu MA. (1993). Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension 21:816-826.
3. Beckman JA, Creager MA. (2006). The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 16:156-162.
4. Boodhwani M, Nakai Y, Voisine P, Feng J, Li J, Mieno S, et al. (2006). High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 114:I402-I408.
5. Bray GA. (1977). The Zucker-fatty rat: a review. Fed Proc 36:148-153.
6. Bucay M, Nguy J, Barrios R, Chen CH, Henry PD. (1998). Impaired adaptive vascular growth in hyper-cholesterolemic rabbit. Atherosclerosis 139:243-251.
7. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. (2005). Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and infl ammation. Circulation 111:1448-1454.
8. Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, et al. (2003). Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clin Cardiol. 26:509-514.
9. Duarte J, Martinez A, Bermejo A, Vera B, Gamez MJ, Cabo P, et al. (1999). Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur J Pharmacol 365:225-232.
10. Endres M. (2006). Statins: potential new indications in infl ammatory conditions. Atheroscler Suppl. 7:31-35.
11. Field KM. (2005). Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharma-cotherapy 25:1365-1377.
12. Frisbee JC, Balch Samora J, Peterson J, Bryner R. (2006). Exercise training blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ Physiol 291:H2483-H2492.
13. Frisbee JC. (2006). Impaired hemorrhage tolerance in the obese Zucker rat model of metabolic syndrome. J Appl Physiol 100:465-473.
14. Frisbee JC. (2006). Vascular adrenergic tone and structural narrowing constrain reactive hyperemia in skeletal muscle of obese Zucker rats. Am J Physiol Heart Circ Physiol 290:H2066-H2074.
15. Frisbee JC. (2005). Reduced nitric oxide bioavaila-bility contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 289:R307-R316.
16. Frisbee JC. (2005). Hypertension-independent micro-vascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation. 12:383-392.
17. Frisbee JC. (2004). Enhanced arteriolar alpha-adrenergic constriction impairs dilator responses and skeletal muscle perfusion in obese Zucker rats. J Appl Physiol 97:764-772.
18. Frisbee JC. (2003). Impaired skeletal muscle perfu-sion in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 285:R1124-R1134.
19. Frisbee JC. (2003). Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats. Am J Physiol Heart Circ Physiol 285:H104-H111.
20. Ginsberg HN. (2006). Effi cacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 91:383-392.
21. Greene AS, Lombard JH, Cowley AW, Jr, Hansen-Smith FM. (1990). Microvessel changes in hypertension measured by Griffonia simplicifolia I lectin. Hypertension 15:779-783.
22. Guerre-Millo M. (1997). Regulation of ob gene and over expression in obesity. Biomed Pharmacother. 51:318-323.
23. Hardman JG, Limbird LE, Gilman AG, eds . ( 2001). Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 10th ed. (pp. 971-1002). New York: McGraw-Hill.
24. Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, et al. (2004). Effects of conventional and aggressive statin treatment on markers of endothelial function and infl ammation. Clin Cardiol 27:199-203.
25. John S, Delles C, Jacobi J, Schlaich M P, Schneider M, Schmitz G, et al. (2001). Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 37:1351-1358.
26. Knopp RH, Paramsothy P. (2006). Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare? Nat Clin Pract Endocrinol Metab 2:136-137.
27. Laufs U, La Fata V, Plutzky J, Liao JK. (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135.
28. Libby P. (2002). Infl ammation in atherosclerosis. Nature 420:868-874.
29. Lyon CJ, Law RE, Hsueh WA. (2003). Minireview: adiposity, infl ammation, and atherogenesis. Endocrinology 144:2195-2200.
30. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. (2001). HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159:27-33.
31. Mason RP, Walter MF, Day CA, Jacob RF. (2005). Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11F-23F .
32. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006;99:69-77.
33. Pirro M, Schillaci G, Savarese G, Gemelli F, Vaudo G, Siepi D, et al. (2004). Low-grade systemic infl am-mation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 34:335-341.
34. Ray KK, Cannon C P. (2005). The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46:1425-1433.
35. Sasaki K, Duan J, Murohara T, Ikeda H, Shintani S, Shimada T, et al. (2003). Rescue of hypercholesterole-mia-related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol 42:364-372.
36. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, et al. (2004). Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43:1214-1220.
37. Shige H, Dart A, Nestel P. (2001). Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 155:245-250.
38. Skaletz-Rorowski A, Walsh K. (2003). Statin therapy and angiogenesis. Curr Opin Lipidol 14: 599-603.
39. Smilde TJ, van den Berkmortel F W, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef A F. (2000). The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 30:473-480.
40. Stokes KY. (2006). Microvascular responses to hypercholesterolemia: the interactions between innate and adaptive immune responses. Antioxid Redox Signal 8:1141-1151.
41. Theilmeier G, Verhamme P, Dymarkowski S, Beck H, Bernar H, Lox M, et al. (2002). Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary fl ow reserve and reduced capillary density. Circulation 106:1140-1146.
42. Tofovic S P, Jackson EK. (2003). Rat models of the metabolic syndrome. Meth Mol Med 86:29-46.
43. Ubels FL, Muntinga JH, van Doormaal JJ, Reitsma WD, Smit AJ. (2001). Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. Atherosclerosis 154:155-161.
44. Van Belle E, Rivard A, Chen D, Silver M, Bunting S, Ferrara N, et al. (1997). Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 96:2667-2674.
45. van Haelst PL, van Doormaal JJ, Asselbergs F W, van Roon AM, Veeger NJ, Henneman MM, et al. (2003). Correlates of endothelial function and their relationship with infl ammation in patients with familial hypercholesterolaemia. Clin Sci (Lond) 104:627-632.
46. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, Natarajan R. (2005). Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int 68:2787-2793.
47. Walker AB, Chattington PD, Buckingham RE, Williams G. (1999). The thiazolidinedione, rosiglita-zone, (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes ;48:1448-1453.
48. Weis M, Heeschen C, Glassford AJ, Cooke J P. (2002). Statins have biphasic effects on angiogenesis. Circulation 105:739-745.
49. Xiang L, Naik JS, Abram SR, Hester RL . 2006. Chronic hyperglycemia impairs functional vasodi-lation via increasing thromboxane receptor-mediated vasoconstriction. Am J Physiol Heart Circ Physiol 11 Aug [Epub ahead of print] .
50. Xiang L, Naik JS, Hodnett BL, Hester RL. (2006). Altered arachidonic acid metabolism impairs func tional. vasodilation in metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 290:R134-R138.
51. Xiang L, Naik J, Hester RL. (2005). Exercise-induced increase in skeletal muscle vasodilatory responses in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 288:R987-R991.
52. Zhou Z, Rahme E, Pilote L. (2006) Are statins created equal? Evidence from randomized trials of prava-statin, simvastatin, and atorvastatin for cardio vascular disease prevention. Am Heart J 151:273-281